Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

Explore-OSA

57 evidence topics · 10 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Phase“Phase 2”
Enrollment (actual)“48”
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit or history of diabetic ketoacidosis in the 6 months prior to the Screening Visit” (opens the source at this quote in a new tab)

“Participants on a glucagon-like peptide-1 (GLP-1) agonist.” (opens the source at this quote in a new tab)

“Have diagnosis of central or mixed sleep apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration” (opens the source at this quote in a new tab)

“Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia” (opens the source at this quote in a new tab)

“Use of bilevel positive airway pressure (BiPAP) therapy.” (opens the source at this quote in a new tab)

“eGFR less than (<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) at Screening using serum creatinine or cystatin-C” (opens the source at this quote in a new tab)

“Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1 month of the Screening Visit” (opens the source at this quote in a new tab)

“Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6 months prior to Screening” (opens the source at this quote in a new tab)

“Previously diagnosed, recurrent orthostatic hypotension” (opens the source at this quote in a new tab)

“Current night-shift worker or anticipated to become a night-shift worker for 3 days continuously during the duration of the study.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Summary: systolic blood pressure figures in the congress abstract and the company releases

The congress abstract reports the preplanned parallel-arm analysis of the first treatment period as a placebo-adjusted reduction in systolic blood pressure of 10.1 mmHg (P=0.0089). The NDA acceptance release and the AHA Hypertension 2026 release report within-group reductions of 11.1 mmHg with lorundrostat (p<0.0001) and 1.0 mmHg with placebo (p=NS) at week 4, and the NDA acceptance release attributes these figures to the pre-planned parallel arm analysis of the first period; the difference between the two within-group figures is 10.1 mmHg. The abstract and the NDA acceptance release both report a placebo-adjusted reduction of 6.2 mmHg (P<0.0003) in the crossover analysis of both treatment periods. The NDA acceptance release reports topline results.

Nighttime blood pressure

No evidence found.

Health-related quality of life and patient-reported outcomes
Epworth Sleepiness Scale and PROMIS sleep measures

No evidence found.

Safety results
Study limitations
Summary

Explore-OSA was a phase 2 crossover trial with two 4-week treatment periods separated by a 2-week washout; the registry lists 48 enrolled participants and the congress abstract describes 47. The primary endpoint, the placebo-adjusted change in apnea-hypopnea index at week 4, showed “no difference in AHI response between lorundrostat- and placebo-treated participants”. Office systolic blood pressure was a secondary endpoint, and the public results come from a congress abstract and company releases; no peer-reviewed publication or posted registry results were located, and the registry record shows a certification/extension submission dated 2026-08-17. The registry lists nighttime average systolic blood pressure as the first secondary outcome measure and also lists the Epworth Sleepiness Scale and two PROMIS sleep measures; no result for any of these was located in the public documents. The parallel-arm systolic blood pressure estimate uses the first treatment period alone, and the abstract and the company releases state it differently. The abstract states that “more than a third of participants were using PAP therapy”. Public safety reporting is limited to the absence of serious adverse events and of serum potassium values above 5.5 mmol/L. Eligibility excluded participants with eGFR below 45 mL/min/1.73 m2 and participants taking a GLP-1 agonist, and the registry lists 27 locations.